Phase IIA trial testing erlotinib as an intervention against intraductal pancreatic mucinous neoplasms.

ABSTRACT: Intraductal papillary mucinous neoplasms (IPMN) are a distinct type of precursor lesions that cause about 5% of pancreatic adenocarcinoma (1, 2). Four-year survival rates of 40% to 75% are reported (3-7). There is currently no chemotherapy specifically approved for treating IPMNs. The number of IPMN cases has significantly increased over the last decade (8).

SUBMITTER: Lipkin S 

PROVIDER: S-EPMC4492452 | biostudies-literature | 2011 Apr

REPOSITORIES: biostudies-literature